Intelligence Platform
Clinical trials, SEC filings,
hedge fund positioning,
and how they connect.
One database, organized by company, updated daily from primary sources. Built for BD, investors, and strategy teams.
$499/mo
Cancel anytime. Access continues through the end of the billing period.
Live Platform Data
On the platform right now, from primary sources.
Updated May 19, 2026
Endpoint modifications, enrollment shifts, and status changes detected automatically for every registered trial.
The primary endpoint was changed from 'Incidence of adverse events' to 'Incidence of Adverse Events' with an extended timeframe from Week 24 to Week 116. Additionally, three new secondary endpoints were added: 'Kaplan-Meier Estimate for Time to First GPP Flare Recurrence (Weeks)', 'Percentage of Subjects Maintaining GPPPGA Score of 0 or 1', and 'Percentage of Subjects With Zero Recurrence of GPP Flare'.
Completion date: 2026-02-25 → 2026-05-29
Trial stopped: The study was terminated based on strategic evaluation of the clinical development of HMPL-306 with no safety concerns
Hedge fund ownership disclosures: who's building positions, reducing stakes, or going activist. Cross-referenced with trial events and 8-Ks.
Cormorant Asset Management, LP
BVF Partners L.P.
Cormorant Asset Management, LP
8-K filings classified by type: licensing deals, FDA actions, financing events, and strategic reviews, identified automatically.
Context Therapeutics Inc. amended its license agreement with BioAtla, Inc. for exclusive rights to certain antibody assets, including CT-202. The amendment makes the licenses irrevocable, royalty-free, fully paid-up, and non-terminable, eliminating future milestone payments and royalties to BioAtla. Context Therapeutics will pay BioAtla $4.5 million within five business days and an additional $2.0 million by August 1, 2026 for these modified terms.
Atara Biotherapeutics, Inc. announced a regulatory update regarding its drug EBVALLO™. The company held a Type A meeting with the FDA to discuss the Complete Response Letter (CRL) issued on January 9, 2026, for the EBVALLO™ Biologics License Application.
Genprex announced positive preclinical data for its diabetes gene therapy, GPX-002 (Pdx1/MafA gene therapy), presented at the ASGCT Annual Meeting. The data demonstrated that the therapy reversed hyperglycemia and improved beta-cell function and maturation in Type 2 diabetic mouse models. This preclinical success is considered a pivotal step towards a potentially transformative treatment for T2D, aiming for long-term glycemic control by directly addressing beta-cell dysfunction.
All items link to original SEC documents and registry records on the platform.
Data
Primary sources, all linked.
Every data point traces to the original filing or registry record. No news, no analyst commentary, no third-party data vendors.
ClinicalTrials.gov
450K+ trials. Status, enrollment, endpoints, results, and change tracking. Updated daily.
SEC EDGAR
8-K, 10-K, 10-Q, Form 4, 13D/13G, 13F and more. Parsed and classified. Updated multiple times daily.
Financial Data
Filter companies by market cap, cash, expenses, and more for 500+ biotech companies.
FDA Data
Drug products, patent listings, and exclusivity records. Integrated
app.rxdatalab.com
What you can do
Built for BD, investors, and strategy teams who work from primary sources rather than news and analyst commentary.
Track a company across every source
Trial pipeline, 8-Ks, Regulatory filings, and financials in one view. Every item links to the original source document or registry record.
Monitor trial changes automatically
Daily comparison against ClinicalTrials.gov catches endpoint modifications, enrollment changes, arm updates, and status shifts. Nothing buried in the registry.
See who's building positions in biotech
Fund profiles with full position history and filing records. Multi-fund convergence on the same company. 13D/G cross-referenced with 8-K events and trial milestones.
See live data sample →Search SEC filings by what they mean
8-K filings classified into financing events, FDA actions, clinical results, licensing deals, and strategic reviews. Search by company, date range, or filing type, not just keyword.
See live data sample →Map competitive landscapes
Search by indication and surface every company running trials for that indication or related indications. Overlay financial position and recent trial events across the competitive field.
Organize research with projects and notes
Create projects with company and trial watchlists. Add timestamped notes directly on company and trial pages. Dashboard shows what changed across your coverage since your last session.
Data In Context
Every event, in context.
Financing events, licensing deals, trial changes, and hedge fund moves — overlaid on the quarterly financial timeline for Solid Biosciences Inc. (SLDB). Toggle layers, hover annotations, click any event to see the original source.
Competitive Landscape
Explore the competitive biotech landscape.
Search any indication. We map every industry trial using the NLM's MeSH medical ontology, then overlays institutional ownership, financial position, and recent trial events across the competitive field.
Condition Landscape
Active industry trials per condition. Search any condition on the platform.
Active Sponsors
| Company | Mkt Cap | Trials | Cash | Qtr Exp |
|---|---|---|---|---|
| Cullinan Therapeutics, Inc. CGEM | $914M | 1 | $75M | $54M |
| Allogene Therapeutics, Inc. ALLO | $669M | 1 | $30M | $46M |
| Autolus Therapeutics plc AUTL | $479M | 1 | $131M | $61M |
| C4 Therapeutics, Inc. CCCC | $356M | 3 | $61M | $34M |
| COMPUGEN LTD CGEN | $270M | 1 | — | — |
| Caribou Biosciences, Inc. CRBU | $205M | 2 | $12M | $29M |
| Karyopharm Therapeutics Inc. KPTI | $162M | 2 | $91M | $60M |
| Senti Biosciences, Inc. SNTI | $29M | 1 | $12M | $12M |
Sample data. Financial data from parsed 10-K/Q filings. Qtr Exp = R&D + G&A per quarter.
Trial monitoring
Trials can quietly change, don't miss it
Daily comparison against ClinicalTrials.gov. Every endpoint modification, enrollment shift, and status change categorized and summarized automatically.
NCT04762602
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
HUTCHMED (China) Ltd HCM
Enrollment
42
Primary Completion
2025-02
Detected
Mar 28, 2026
Primary endpoint timeframe
+ 3 more changes detected
AI Summary
A new primary endpoint, Recommended Phase 2 Dose (RP2D) of HMPL-306, was added. The primary endpoint 'Frequency and severity of AEs' was rephrased to 'Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)' with a slightly extended timeframe. The secondary endpoint 'Clinical Benefit Rate (CBR)' was replaced with 'Disease Control Rate (DCR)' and a new secondary endpoint, 'Maximum Inhibition Rate of Plasma 2-Hydroxyglutaric Acid (2-HG)', was added. Additionally, 'Time to Response (TTR)' was added as a new secondary endpoint.
Full change history per trial. Every detection timestamped and linked to the original registry record.
Subscribe to access →Pricing
Simple, transparent pricing.
Individual — Monthly
Billed monthly. Cancel anytime from your account page.
- ✓ Full platform access
- ✓ BioHedge (13D/G fund positioning)
- ✓ Clinical trial change detection
- ✓ 8-K signal detection
- ✓ Competitive landscape mapping
- ✓ Research workspace and notes
Teams & Institutions
Custom pricing
For teams, firms, and institutional users who need multi-seat access, custom coverage, AI Access, API Access, or enterprise billing.
- ✓ Multi-seat access
- ✓ Custom data coverage and exports
- ✓ Invoiced billing and enterprise contracts
- ✓ API access and custom data feeds
- ✓ Dedicated support
or email [email protected]
Got it — we'll be in touch.
Expect a reply within one business day.
What happens after payment?
You'll receive a welcome email with a link to set your password. Access immediately once your password is set.
How do I cancel?
Go to your account page and click "Manage Billing." Access continues through the end of your billing period.
Do you offer trials or demos?
The public pages at app.rxdatalab.com/biohedge and app.rxdatalab.com/strategic-signals show live data and require no login.
Questions or enterprise pricing?
Email [email protected] for team access, institutional pricing, or anything else.
By subscribing you agree to our Terms of Service and Data License Agreement.